Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of ALMDT.PA is 13 and suggests 124% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc